Not all cosmetic test reports are created equal: some are rejected by regulators, and some aren’t internationally recognized. Choosing the wrong laboratory can delay your product launch or even block market entry entirely. This article explains the differences between CMA, CNAS, and ISO 17025 accreditation, why they matter for cosmetic testing in China, and how to select the right lab for regulatory compliance.
On May 29, 2026, China's STSC underwent a significant update. To accompany this update, China's NIFDC simultaneously released official supporting Q&As. CIRS Group has compiled and organized the information below for your reference.
On February 2, 2026, the Taiwan Food and Drug Administration (TFDA), under the Ministry of Health and Welfare, announced a revision to the annex of the Documentation Required for Case-by-Case Review of Applications for the Use of Human Cell-Derived Exosomes in Cosmetics. The revised annex takes effect immediately upon the date of announcement.
Since the concept of New Approach Methodologies (NAMs) was introduced, various methods including in vitro approaches, Threshold of Toxicological Concern (TTC), and computational models have gained favor among toxicological assessment experts. With the increasing capabilities of computational models, key toxicological endpoints such as acute toxicity, skin/eye irritation, sensitization, chronic toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and toxicokinetics can now be predicted using QSAR models.
Contact Us
